Physician profile
Samuel Brown
NPI 1104810605
$4,963.24
in general payments reported to CMS, 2019-2025
15 companies · $37.08 in 2025
The $37.08 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $55.66 · 2021: $221 · 2022: $151 · 2023: $4,339 · 2024: $34.59 · 2025: $37.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,091 · Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,090.95 |
| Food and Beverage | $319.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,150.00 | 2023 | Da Vinci Surgical System |
| Abbvie INC. | $189.93 | 2020-2022 | |
| Astellas Pharma US INC | $136.64 | 2023 | Veozah |
| Coopersurgical, INC. | $110.25 | 2019 | |
| Medtronic, INC. | $104.50 | 2022 | |
| Hologic Sales and Service, LLC | $66.36 | 2019-2025 | Aptima |
| Exeltis, USA INC. | $37.53 | 2021-2022 | |
| Pfizer INC. | $36.23 | 2023-2024 | |
| Lupin INC. | $29.84 | 2020 | |
| Organon LLC | $29.64 | 2021-2023 | Nexplanon |
| Mayne Pharma Commercial LLC | $20.12 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $15.60 | 2024 | Flumist Quadrivalent |
| Evofem Biosciences, INC. | $12.49 | 2021 | |
| Merck Sharp & Dohme LLC | $12.38 | 2021 | |
| Avion Pharmaceuticals | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.